

10. (NEW) A monoclonal antibody of claim 4, which specifically binds with a peptide having the amino acid sequence of SEQ ID NO: 11.

11. (NEW) A method for detecting 19P2 ligand in a sample, comprising assaying said sample with a monoclonal antibody of claim 10 and detecting such binding.

12. (NEW) A monoclonal antibody of claim 1, which specifically binds with a peptide having the amino acid sequence of SEQ ID NO: 7.

13. ~~14.~~ (NEW) A method for detecting 19P2 ligand in a sample, comprising assaying said sample with a monoclonal antibody of claim 12 and detecting such binding.

14. ~~15.~~ (NEW) A method for detecting 19P2 ligand in a sample, comprising assaying said sample with a monoclonal antibody of claim 10 and an antibody which specifically binds to a peptide having the amino acid sequence of SEQ ID NO: 7, detecting such binding.

15. ~~16.~~ (NEW) A method for diagnosing hyperprolactinemia comprising an assay using the method of claim 11.

16. ~~17.~~ (NEW) A method for diagnosing hyperprolactinemia comprising an assay using the method of claim 12.

17. ~~18.~~ (NEW) A method for diagnosing hyperprolactinemia comprising an assay using the method of claim 13.

18. ~~19.~~ (NEW) A monoclonal antibody of claim 4, which specifically binds with a peptide having the amino acid sequence of SEQ ID NO: 1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:5, or SEQ ID NO:12.

19. ~~20.~~ (NEW) A monoclonal antibody of claim 4, which specifically binds with a peptide having the amino acid sequence of amino acid residues 12 to 24 of SEQ ID NO: 1, amino acid residues 12 to 24 of SEQ ID NO: 2, or amino acid residues 12 to 24 of SEQ ID NO: 3.

20. ~~21.~~ (NEW) A monoclonal antibody of claim 4, which specifically binds with a 19P2 ligand peptide, but which does not bind with a peptide having the amino acid sequence of SEQ ID NO: 4 or SEQ ID NO: 6.

21. ~~22.~~ (NEW) A monoclonal antibody of claim 4, which is P2L-1Ta.

22. ~~23.~~ (NEW) A monoclonal antibody of claim 4, which is P2L-3Ta.

23. ~~24.~~ (NEW) A monoclonal antibody of claim 4, which is P2L-1Ca.

*A
J
C 10*

~~24~~ 25. (NEW) A monoclonal antibody of claim 4, which is P2L-2Ca.

~~25~~ 26. (NEW) An isolated hybridoma cell line, said cell line producing the antibody P2L-1Ta, P2L-3Ta, P2L-1Ca or P2L-2Ca.

~~26~~ 29. (NEW) A method of claim ~~15~~¹⁴ for detecting 19P2 ligand in a sample, comprising assaying said sample wherein said 19P2 ligand is attached to a carrier.

~~27~~ 30. (NEW) A method of claim ~~15~~¹⁴ wherein a monoclonal antibody is attached to a carrier.

~~28~~ 31. (NEW) A method of claim ~~15~~¹⁴ wherein a monoclonal antibody is attached to a detectable signal or label.

~~29~~ 32. (NEW) A method of claim ~~15~~¹⁴ which is a sandwich assay.

~~30~~ 33. (NEW) A method of claim ~~15~~¹⁴ which is a competitive inhibition assay.

~~31~~ 34. (NEW) A method of claim ~~15~~¹⁴ in which one monoclonal antibody is P2L-1Ta, P2L-3Ta, P2L-1Ca or P2L-2Ca.

13, 27, 28 = M13⁸⁹ug